1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag

Abliva AB Interim Report January – September 2024

MARKN.

- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -

Third Quarter Summary

Important events July - September 2024

  • In July, Abliva announced a positive outcome of the interim analysis of the 24-week data of the FALCON study with KL1333, increasing the probability of a positive readout upon completion of the full study.
  • Following the positive outcome of the interim analysis, Abliva was provided with additional proceeds of SEK 42 million before transaction costs through the conversion of the convertible bonds pledged in the capital raise earlier this year.

Financial information

July-September 2024*

  • Net revenues: SEK 0 (0)
  • Other operating income: SEK 0 (0)
  • Loss before tax: SEK 19,541,000 (32,942,000)
  • Loss per share before dilution: SEK 0.01 (0.03)
  • Diluted loss per share: SEK 0.01 (0.03)

January-September 2024*

  • Net revenues: SEK 0 (0)
  • Other operating income: SEK 290,000 (2,783,000)
  • Loss before tax: SEK 63,474,000 (70,260,000)
  • Loss per share before dilution: SEK 0.05 (0.07)
  • Diluted loss per share: SEK 0.05 (0.07)

* APM Alternative performance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva’s website www.abliva.com.

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com. Subscribe to our news and follow us on LinkedIn and YouTube.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Attachments

Abliva Interim report Jan - Sep 2024

Datum 2024-11-29, kl 18:00
Källa MFN
Bifogade filer
Abliva Interim report Jan - Sep 2024
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!